rs773539640
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_206933.4(USH2A):βc.1679delβ(p.Pro560LeufsTer31) variant causes a frameshift change. The variant allele was found at a frequency of 0.0000508 in 1,613,932 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Pathogenic (β β ). Variant results in nonsense mediated mRNA decay.
Frequency
Genomes: π 0.000013 ( 0 hom., cov: 32)
Exomes π: 0.000055 ( 0 hom. )
Consequence
USH2A
NM_206933.4 frameshift
NM_206933.4 frameshift
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: 6.80
Genes affected
USH2A (HGNC:12601): (usherin) This gene encodes a protein that contains laminin EGF motifs, a pentaxin domain, and many fibronectin type III motifs. The protein is found in the basement membrane, and may be important in development and homeostasis of the inner ear and retina. Mutations within this gene have been associated with Usher syndrome type IIa and retinitis pigmentosa. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Dec 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 18 ACMG points.
PVS1
Loss of function variant, product undergoes nonsense mediated mRNA decay. LoF is a known mechanism of disease.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 1-216292335-AG-A is Pathogenic according to our data. Variant chr1-216292335-AG-A is described in ClinVar as [Pathogenic]. Clinvar id is 286104.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr1-216292335-AG-A is described in Lovd as [Pathogenic]. Variant chr1-216292335-AG-A is described in Lovd as [Likely_pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
USH2A | NM_206933.4 | c.1679del | p.Pro560LeufsTer31 | frameshift_variant | 10/72 | ENST00000307340.8 | NP_996816.3 | |
USH2A | NM_007123.6 | c.1679del | p.Pro560LeufsTer31 | frameshift_variant | 10/21 | NP_009054.6 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
USH2A | ENST00000307340.8 | c.1679del | p.Pro560LeufsTer31 | frameshift_variant | 10/72 | 1 | NM_206933.4 | ENSP00000305941 | P1 | |
USH2A | ENST00000366942.3 | c.1679del | p.Pro560LeufsTer31 | frameshift_variant | 10/21 | 1 | ENSP00000355909 | |||
USH2A | ENST00000674083.1 | c.1679del | p.Pro560LeufsTer31 | frameshift_variant | 10/73 | ENSP00000501296 |
Frequencies
GnomAD3 genomes AF: 0.0000131 AC: 2AN: 152216Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
2
AN:
152216
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000239 AC: 6AN: 251252Hom.: 0 AF XY: 0.0000147 AC XY: 2AN XY: 135796
GnomAD3 exomes
AF:
AC:
6
AN:
251252
Hom.:
AF XY:
AC XY:
2
AN XY:
135796
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000547 AC: 80AN: 1461716Hom.: 0 Cov.: 31 AF XY: 0.0000399 AC XY: 29AN XY: 727156
GnomAD4 exome
AF:
AC:
80
AN:
1461716
Hom.:
Cov.:
31
AF XY:
AC XY:
29
AN XY:
727156
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000131 AC: 2AN: 152216Hom.: 0 Cov.: 32 AF XY: 0.00 AC XY: 0AN XY: 74364
GnomAD4 genome
AF:
AC:
2
AN:
152216
Hom.:
Cov.:
32
AF XY:
AC XY:
0
AN XY:
74364
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:10
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Feb 17, 2016 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Apr 23, 2015 | The c.1679delC variant in the USH2A gene has been reported in association with Usher syndrome type 2A (Weston et al., 2000). The deletion causes a frameshift starting with codon Proline 560, changes this amino acid to a Leucine residue and creates a premature Stop codon at position 31 of the new reading frame, denoted p.Pro560LeufsX31. The c.1679delC variant is predicted to cause loss of normal protein function either through protein truncation or nonsense-mediated mRNA decay. Therefore, we interpret this variant as pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 30, 2023 | This sequence change creates a premature translational stop signal (p.Pro560Leufs*31) in the USH2A gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in USH2A are known to be pathogenic (PMID: 10729113, 10909849, 20507924, 25649381). This variant is present in population databases (rs773539640, gnomAD 0.01%). This premature translational stop signal has been observed in individuals with Usher syndrome 2A (PMID: 10729113, 15325563, 15671307, 22135276, 25649381). ClinVar contains an entry for this variant (Variation ID: 286104). For these reasons, this variant has been classified as Pathogenic. - |
Retinitis pigmentosa 39 Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Nov 04, 2023 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Feb 28, 2024 | - - |
Pathogenic, no assertion criteria provided | clinical testing | Counsyl | Aug 18, 2017 | - - |
Usher syndrome type 2A Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Nov 04, 2023 | - - |
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Jul 14, 2020 | - - |
Usher syndrome type 2A;C3151138:Retinitis pigmentosa 39 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Oct 12, 2021 | - - |
Retinal dystrophy Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Blueprint Genetics | Jul 26, 2019 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at